Levofloxacin

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 1, 1999, Pages 109-119

  Ragnar Norrby, S ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OFLOXACIN;

ANIMAL; BACTERIAL INFECTION; BACTERIUM; CLINICAL TRIAL; DRUG EFFECT; HUMAN; MICROBIOLOGY; REVIEW;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS; HUMANS; OFLOXACIN;

EID: 0033224459     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.1.109     Document Type: Article

References (52)

1. HAYKAWA I, ATARASHI A, YOKAHAMA S et (il.: Synthesis and antibacterial activities of optically active ofloxacin. Antlmlcrub. Age-uts Cbcniotbcr. (1986) 29:163-16-4.
2. ISAACSON DM, FERNANDEZ JA, FROSCO M et al.: Levofloxacin: a review of its antibacterial activity. Recent Res. Dei: Anliniicmb. Agents Chenmther. (1996) 1:391-439. • A thorough review.
3. UNE T, FUJIMOTO T, SATO K et al.-. In vitro activity of DR-3355, and optically active ofloxacin. Aiilimicrub. Agents Chcmother. (1988) 32:1336-13-40.
4. ENG KHK, SMITH SS, FAN-HAVARD P et eil.-. Effect of antibiotics on cndotoxin release from Gram-negative bacteria. Diagn. Micmbiol. Infect. Dis. (1993) 16:185-189.
5. VISALL! MA, JACOBS MR, APPELBAUM PC: Susceptibility of twenty penicillin-susceptible and -resistant pncumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, and claritliromycin by MIC and time-kill. Diagii. Micmbiol. Infect. Dis. (1997) 28:131-137. • Imponnnt comparison of the activity of various antibiotics on penicillin-resistant pneumococci.
6. GEORGE J, MORR1SSEY I: The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumonia.J.Antimlcrob.Cbemother. (1997) 39:719-723.
7. LAFREDO SC, FOLENO BD, FU KP: Induction of resistance of Streptococcus pnctitnoniae to quinoloncst vitro. Chemotherapy (1993) 39:36-39-
8. THORNSBERRY C, OGILVE P, KAHN J et al.: Surveillance of antimicrobial resistance in Streptococcus pneunionine, Haemopbilus influenzae and Moraxella catarrbalis In the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. (1997) 29:249-257.
9. CHEN DK, MCGEER A, DE AZEVADO JC et al.: Decreased susceptibility of Streptococcus pneiinioniae to fluoroquinoloiics in Canada. A'CM' Engl. J. Meel. (1999) 341:233-239. Very important observation of increased frequencies of fluoroquinolone resistance in pneumococci.
10. LEVIN CS, MORR1SEY I, SMITH JT: The fluoroquinoloncs exert a reduced rate of kill against Enterococcus faecalis.J. Pbarm. Pbannacol. (1991) 43:492-491.
11. YAMAIJ E, AKIEDA Y, WATANABE T et al.: In rilro antibacterial activity of levofloxacin against MKSA. Drugs W95) 45(Suppl. 3):210.
12. MICHELET C, AVRIL JL, ARVIEUX et al: Comparative activities of new fluoroquinoloncs, alone or in combination with amoxicillin, trimcthoprimsulfamcthoxazolc, or rifampicin, against intraccllular Listeria nwiiocytogcnes. Aiitimicrob. Agents Cbemotber. (1997) 41:60-65.
13. VISALLI M, BAJAKSOUZIAN S, JACOBS U et al,: Comparative activity of trovafloxacin, alone or in combination with other agents, against Gram-negative nonfcrmentative rods. Antlmicrob. Agents Chemotbcr. (1997) 41:1475-1481.
14. FKEAN JA, ARNTZEN L, CAPPER T et al.-.In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a Southern Africa plague focus, Antimicrob. Agents Cbemotber. (1996) 40:2646-2647.
15. HOPPE JE. RAHIMI-GALOUGAHI E, SEIBERT G: In vitro susceptibilities ofBordetella pertussis andBordetella parapertussts to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropeneni. Antimicrob. Agents Chcmolbcr. (1996) 40:807-808.
16. MOR N, VANDERVOLK J, HEIFERTS L: Inhibitory and bactericidal activities of levofloxacin against Mycobac-terium tuberculosis in vitro and in human macrophages. Antlmlcmb. Agents Cheinolber. (1994) 38:1161-1164.
17. RASTOGI N, GOH KS, BRYSKIER A et al.-. Spectrum of activity of levofloxacin against nontubcrculous mycobacteria and its activity against the Mycobaclcrium ai'iuni complex in combination with cthambutol, rifanipin, roxitliromycin, amikacin and clofazimine. Antimicrob. Agents Cbemotbcr. (1996) 40:2483-2487. • Thorough evaluation of the efficacy of levofloxacin and combinations of levofloxacin and antimycobacterial drugs against non-tuberculous mycobacteria.
18. GOLDSTEIN EJC, CITRON DM, HUDSPETH M et al.: Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J. Antimicrob. Chemother. (1998) 41:391-396.
19. MADINGER NE, MCGREGOR JA, MCKINNEY PJ et al.: Comparative antibiotic susceptibilities of anaerobes associated with infections of the female reproductive tract. Clin. Infect. Dis. (1993) !6(SuppI. 4):S49-52.
20. HAMMERSCHLAG M: Antimicrobial susceptibility and therapy of infections caused by Cblamydia ptieinno-niae.Antimicmb. Agents Chemother. (1994) 38:1873-1878. Systematic study of the activity of antibiotics against Cblamydia trachomatis.
21. SCHÜLIN T, WENNERSTEN CB, FERRARO MJ et ai: Susceptibilities oflcgioiiella spp. to newer antimicrobials in vitro. Antimicrob. Agents Cbeiuotber.WVS) 42:1520-1525.
22. ENTENZA JM, VOUILLAMOZ J, GLAUSER MP et al.: Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to mcthicillin-susccptiblc or -resistant Stapbylococcus aiireus. Antimicrob. Agents Cbemotber. (1997) 41:1662-1667. • Important study demonstrating in vil-o efficacy of fluoroquinolones in endocarditis.
23. NAU K, SCHMIDT T, KAYE K ctal.: Quinolonc antibiotics in experimental pncumococcal meningitis in rabbits. Antlmtcmb. Agents Cbemotber. (1995) 39093-597. • Important study verifying efficacy of fluoroquinolones in experimental meningitis.
24. KLEMENS SP, SHARPE CA, KOGGE MC el al.: Activity of levofloxacin in a murine model of tuberculosis. Antimicmb. Agents Chemother. (1994) 38:1476-1479.
25. TANAKA M, UNE T, OSADA Y: Sub-inhibitory and post-antibiotic effects of an optically active isomer of ofloxacin. Dnig Res. (1989) 39:750-751
26. HOUSTON AK, JONES RN: Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn. Micmbiol. Infect. Dis. (1994) 18:57-59
27. SPANGLER SK, LIN G, JACOBS MR et dl.: Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci. Antimicmb. Agents Cbemotber. (1998) 42:1253-1255.
28. ANDES DR, CRAIG WA: Pharmacodynamics of fluoroquinoloncs in experimental models of endocarditis. Clin. Infect. Dis. (1998).27:47-50. Very important evaluation of the optimal dosage of fluoroquinolones.
29. PRESTON SL, DRUSANO GL, HERMAN CL et at.: Pharmacodynamics of levofloxacin. A new paradigm for early clinical trials. JAMA (1998) 279:125-129. • Intriguing suggestions for new modes of drug evaluation.
30. FISH DN. CHOW AT: The clinical pharmacokinetics of levofloxacin. Clin. Pbarmacokinct. (1997) 32:101-119. • Thorough review.
31. GOODWIN SD, GALLIS HA, CHOW AT ctal.: Pharmacokinctics and safety of levofloxacin in patients with human immunodeficiency virus infections. Antimicmb. Agents Cbemotber. ( 1994) 38:799-804.
32. CHILD J, MORTIISOY D, ANDREWS JM: Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antiinicrob. Agents Cbemotber. (1995) 39:2749-2751.
33. ANDREWS JM, HONEYBOURNE D, JEVONS G et al.: Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J. Antimicmb. Chemother. (1997) 40:573-577.
34. FILE TM JR. SECRET! J, DUNBAR L et al.: A multicenter, randomized study comparing the efficacy and safety of intravenous andJor oral levofloxacin versus ceftriaxonc andJor cefuroxime axctil in treatment of adults with community-acquired pneumonia. Antimicmb. Agents Cbemotber. (1997) 41:1965-1972. • Large study of the efficacy and safety of levofloxacin in community acquired pneumonia.
35. NORRBY SU, PETERMANN W, WILLCOX PA et al.: A comparative study of Icvofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scnml.J. Infect. Dis. (1998) 30:397-404. • Large study of the efficacy and safety of levoflox.icin in patients with severe pneumonia, which in most patients was community acquired.
36. HABIB MP, GENTRY LO, RODRIGUEZ-GOMES G et al.: Multicenter, randomized study comparing efficacy and safety of oral Icvofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect. Dis. Clin. Pmct. (1998) 7:191-109.
37. YEW \Wi', AU KF, LEE J et cil.-. Levofloxacin hi the treatment of drug-resistant tuberculosis. Inl.J. Tnbcrc. Lung Dis. (1997) 1:89.
38. KLIMBEKG IW, COX CE, FOWLER CL et ah. A controlled trial of Icvofloxacin and lomcfloxacin in the treatment of complicated urinary tract infection. Urology (V39Ü) 51:610-615-
39. RICHARD GA, KLIMBERG IN, FOWLER CL et al.: Levofloxacin versus ciprofloxacin versus lomefloxacin hi acute pyelonephritis. Urology (1998) 52:51-55.
40. NICHOLS RL, SMITH JT, GENTRY LO et al.-. Multicenter, randomized study comparing Icvofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections. Southern Meä. J. (1997) 90:1193-1200.
41. DA VIS R, BRYSON HM: Levofloxacin. A review of its antibacterial activity, pharmacokinctics and therapeutic efficacy. Drugs (199-0 47:677-700.
42. WAGAI N, YAMAGUCHI F, SEKIGUCHI M et al.: Phototoxic potential of quinolone antibacterial agents hi BALBJc mice. Toxicol. Lett. (1990) 54:299-308.
43. WAGAI N, TAWARA K: Quinolone antibacterial-agentinduccd cutaneous phototoxicity: ear swelling reactions in BALBJc mice. Toxicol. Lett. (1991) 58:215-223.
44. WAGAI N, YOSHIDA M, TAKAYMA S: Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice. Drug Res. (1992) 42:404-405.
45. ADAMANTIDIS MM, DUMOTIER RM, CAKON JF et til.: Sparfloxacin but not Icvofloxacin prolongs cardiac rcpolarization In rabbit Purkinjc fibers. Funclam. Clin, rbannacol. (1998) 12:70-76.
46. AKAHANE K, KATO M, TAKAYAMA S: Involvement of inhibitory and excitatory ncurotransmittcrs in levofloxacin- and ciprofloxacin-induccd convulsions in mice. Antiniicrob. Agents Cbemotber. (1993) 37:1764-1770.
47. KASHIDA Y, KATO M: Characterization of fiuroquinolonc-induced Achilles tendon toxicity in rats: comparison of toxicitics of 10 fluoroquinoloncs and effects of anti-inflammatory compounds. Anttmicrub. Agents Cbemotber. (1997) 41:2389-2393.
48. BURKHARDT JE, WALTERSPIEL JN, SCHAAD UB: Quinolone arthropathy in animals versus children. Clin. Infect. Dis. (1997) 25:1196-120-1. Important evaluation of the possible usefulness of fluoroquinolones in children.
49. ROOSE DR, WALKER SA, CHIEN SC et cil.: Lcvofloxacin does not alter cyclosporin disposition. J. Clin. I'hcmnacol. (1998) 38:90-93.
50. SHIBA K, OKAZAKI O, AOKI H et al.: Influence of antacids and ranitidinc on the absorption of Icvofloxacin in men. DnigsdW) 45(SuppI. 3):299-300.
51. TANAKA M, KURATA T, FUJISAWA C: Mechanistic study of inhibition of Icvofloxacin absorption by aluminium hydroxide. Antiniicrob. Agents Cbemotber. (1993) 37:2173-2178.
52. SHIBA K, SAKAI O, SHIMADA J et al.: Effects of antacids, ferrous sulfate, and ranitidinc on absorption of DR-3355 in humans. Antiinicrub. Agents Cbemolber. (1992) 36:2270-2274.